89 related articles for article (PubMed ID: 11472351)
1. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group.
González M; Barragán E; Bolufer P; Chillón C; Colomer D; Borstein R; Calasanz MJ; Gómez-Casares MT; Villegas A; Marugán I; Román J; Martín G; Rayón C; Debén G; Tormo M; Díaz-Mediavilla J; Esteve J; González-San Miguel J; Rivas C; Pérez-Equiza K; García-Sanz R; Capote FJ; Ribera JM; Arias J; León A; Sanz MA;
Br J Haematol; 2001 Jul; 114(1):99-103. PubMed ID: 11472351
[TBL] [Abstract][Full Text] [Related]
2. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.
Gallagher RE; Willman CL; Slack JL; Andersen JW; Li YP; Viswanatha D; Bloomfield CD; Appelbaum FR; Schiffer CA; Tallman MS; Wiernik PH
Blood; 1997 Aug; 90(4):1656-63. PubMed ID: 9269786
[TBL] [Abstract][Full Text] [Related]
3. Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.
Gupta V; Yib QL; Brandwein J; Chun K; Lipton JH; Messner H; Schuh AC; Wells RA; Minden MD; Kamel-Reidc S
Leuk Lymphoma; 2004 Mar; 45(3):469-80. PubMed ID: 15160908
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases.
Guglielmi C; Martelli MP; Diverio D; Fenu S; Vegna ML; Cantù-Rajnoldi A; Biondi A; Cocito MG; Del Vecchio L; Tabilio A; Avvisati G; Basso G; Lo Coco F
Br J Haematol; 1998 Sep; 102(4):1035-41. PubMed ID: 9734655
[TBL] [Abstract][Full Text] [Related]
5. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
6. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint.
Biondi A; Luciano A; Bassan R; Mininni D; Specchia G; Lanzi E; Castagna S; Cantù-Rajnoldi A; Liso V; Masera G
Leukemia; 1995 Sep; 9(9):1461-6. PubMed ID: 7658712
[TBL] [Abstract][Full Text] [Related]
7. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
Breccia M; Diverio D; Noguera NI; Visani G; Santoro A; Locatelli F; Damiani D; Marmont F; Vignetti M; Petti MC; Lo Coco F
Haematologica; 2004 Jan; 89(1):29-33. PubMed ID: 14754603
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis.
Lin P; Hao S; Medeiros LJ; Estey EH; Pierce SA; Wang X; Glassman AB; Bueso-Ramos C; Huh YO
Am J Clin Pathol; 2004 Mar; 121(3):402-7. PubMed ID: 15023045
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.
Gau JP; Young JH; Lin TH; Yang YS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):175-81. PubMed ID: 10746412
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and laboratory features of patients with CD34(+) acute promyelocytic leukemia].
Liang JY; Wu DP; Liu YJ; Ma QF; Xue YQ; Zhu MQ; Chen ZX
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):196-8. PubMed ID: 19615259
[TBL] [Abstract][Full Text] [Related]
11. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho).
Fukutani H; Naoe T; Ohno R; Yoshida H; Miyawaki S; Shimazaki C; Miyake T; Nakayama Y; Kobayashi H; Goto S
Leukemia; 1995 Sep; 9(9):1478-82. PubMed ID: 7658715
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
13. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.
Kuchenbauer F; Schoch C; Kern W; Hiddemann W; Haferlach T; Schnittger S
Br J Haematol; 2005 Jul; 130(2):196-202. PubMed ID: 16029447
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
15. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
Gu BW; Xiong H; Zhou Y; Chen B; Wang L; Dong S; Yu ZY; Lu LF; Zhong M; Yin HF; Zhu GF; Huang W; Ren SX; Gallagher RE; Waxman S; Chen GQ; Wang ZG; Chen Z; Fu G; Chen SJ
Proc Natl Acad Sci U S A; 2002 May; 99(11):7640-5. PubMed ID: 12032336
[TBL] [Abstract][Full Text] [Related]
16. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
[TBL] [Abstract][Full Text] [Related]
17. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
18. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
[TBL] [Abstract][Full Text] [Related]
19. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
[TBL] [Abstract][Full Text] [Related]
20. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
